The GLP-1 revolution is transforming biopharma M&A strategies, with Novo Nordisk and Eli Lilly leading in obesity drug revenues. Large-cap acquirers are seeking transformative assets, focusing on companies like Viking Therapeutics and Structure Therapeutics. Viking's VK2735 is a dual GLP-1/GIP receptor agonist with promising Phase 2 results and a strong Phase 3 program. Structure is developing a competitive oral GLP-1 franchise with its lead asset, aleniglipron, showing significant weight loss in trials. Both companies present compelling opportunities for acquirers looking to diversify their portfolios.
"Viking Therapeutics is the most direct GLP-1 acquisition target in the sector, with its lead asset, VK2735, showing up to 12.2% body weight reduction in Phase 2."
"Structure Therapeutics is building a best-in-class oral GLP-1 franchise, with its lead asset, aleniglipron, achieving placebo-adjusted mean weight loss of 11.3% and 15.3% in Phase 2b."
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]